JP2562210B2 - ヘコゲニンのエステル誘導体含有医薬組成物 - Google Patents
ヘコゲニンのエステル誘導体含有医薬組成物Info
- Publication number
- JP2562210B2 JP2562210B2 JP1297266A JP29726689A JP2562210B2 JP 2562210 B2 JP2562210 B2 JP 2562210B2 JP 1297266 A JP1297266 A JP 1297266A JP 29726689 A JP29726689 A JP 29726689A JP 2562210 B2 JP2562210 B2 JP 2562210B2
- Authority
- JP
- Japan
- Prior art keywords
- hecogenin
- pharmaceutical composition
- dose
- ester derivative
- composition containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- -1 ester derivative of hecogenin Chemical class 0.000 title claims description 6
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 10
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 10
- VUXXCVWHUXQPFJ-UHFFFAOYSA-N 1-methylsulfanyl-4-methylsulfinyl-6,7-dihydro-5h-cyclopenta[d]pyridazine Chemical group CSC1=NN=C(S(C)=O)C2=C1CCC2 VUXXCVWHUXQPFJ-UHFFFAOYSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 abstract description 12
- OXLGJTRVVNGJRK-UHFFFAOYSA-N Hecogenin Natural products CC1CCC2(CC3CC4C5CCC6CC(O)CCC6(C)C5CC(=O)C4(C)C3C2C)OC1 OXLGJTRVVNGJRK-UHFFFAOYSA-N 0.000 abstract description 2
- UVLDESQWQRMYKD-UHFFFAOYSA-N Neobotogenin Natural products CC1C(C2(C(=O)CC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 UVLDESQWQRMYKD-UHFFFAOYSA-N 0.000 abstract description 2
- 230000001364 causal effect Effects 0.000 abstract description 2
- 230000010261 cell growth Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 241000282414 Homo sapiens Species 0.000 abstract 1
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 230000037396 body weight Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- QOLRLLFJMZLYQJ-LOBDNJQFSA-N Hecogenin Chemical class O([C@@H]1[C@@H]([C@]2(C(=O)C[C@@H]3[C@@]4(C)CC[C@H](O)C[C@@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 QOLRLLFJMZLYQJ-LOBDNJQFSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 231100000460 acute oral toxicity Toxicity 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000011785 NMRI mouse Methods 0.000 description 2
- 108700043492 SprD Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 125000000600 disaccharide group Chemical group 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001529588 Macrolenes <angiosperm> Species 0.000 description 1
- 206010051482 Prostatomegaly Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 241000219422 Urtica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 240000001261 Urtica urens Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
- 125000001483 monosaccharide substituent group Chemical group 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3838716.6 | 1988-11-15 | ||
| DE3838716A DE3838716A1 (de) | 1988-11-15 | 1988-11-15 | Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH02180830A JPH02180830A (ja) | 1990-07-13 |
| JP2562210B2 true JP2562210B2 (ja) | 1996-12-11 |
Family
ID=6367236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1297266A Expired - Fee Related JP2562210B2 (ja) | 1988-11-15 | 1989-11-15 | ヘコゲニンのエステル誘導体含有医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5002939A (https=) |
| EP (1) | EP0369216B1 (https=) |
| JP (1) | JP2562210B2 (https=) |
| AT (1) | ATE90563T1 (https=) |
| BE (2) | BE1002504A3 (https=) |
| DE (2) | DE3838716A1 (https=) |
| ES (1) | ES2057054T3 (https=) |
| GR (1) | GR3008170T3 (https=) |
| IT (1) | IT1229272B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9909110A (pt) * | 1998-03-26 | 2000-12-12 | Phytopharm Plc | Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo |
| GB9923076D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| US6241987B1 (en) * | 1998-08-20 | 2001-06-05 | Amway Corporation | Dietary supplement containing saw palmetto, pumpkin seed, and nettle root |
| GB9923078D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| GB9923077D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| US6261607B1 (en) * | 1999-10-19 | 2001-07-17 | Thomas Newmark | Composition for promoting prostate health containing selenium and herbal extracts |
| GB0000228D0 (en) * | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0107822D0 (en) * | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| US20050130948A1 (en) * | 2002-03-27 | 2005-06-16 | Daryl Rees | Therapeutic methods and uses of sapogenins and their derivatives |
| KR101130212B1 (ko) * | 2002-03-27 | 2012-04-13 | 파이토팜 피엘씨 | 사포게닌 및 그 유도체의 치료 방법 및 사용법 |
| CA2721665C (en) | 2008-04-18 | 2017-01-24 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
| CN109477918A (zh) * | 2016-08-30 | 2019-03-15 | 松下知识产权经营株式会社 | 颜色转换元件 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA582813A (en) * | 1959-09-08 | Elks Joseph | 3.beta., 12.beta.-DIHYDROXY-11-OXO-23-BROMO-5.alpha., 22.alpha.-SPIROSTAN | |
| CA985172A (en) * | 1972-10-06 | 1976-03-09 | Dushan M. Dvornik | Compositions and methods for reducing blood cholesterol |
| US3935194A (en) * | 1974-01-22 | 1976-01-27 | Omni Research Incorporated | Separation of hecogenin-tigogenin mixtures |
| DE2759171A1 (de) * | 1977-12-31 | 1979-07-12 | Roecar Holdings Nv | Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor |
| DE2926463A1 (de) * | 1978-07-05 | 1980-01-24 | Roecar Holdings Nv | Spiroketaline und ihre verwendung |
| GB2024624A (en) * | 1978-07-05 | 1980-01-16 | Roecar Holdings Nv | Anti inflammatory spiroketalins |
| DE3888378T2 (de) * | 1987-04-03 | 1994-09-29 | Merck & Co Inc | Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen. |
-
1988
- 1988-11-15 DE DE3838716A patent/DE3838716A1/de active Granted
-
1989
- 1989-04-26 BE BE8900463A patent/BE1002504A3/fr not_active IP Right Cessation
- 1989-04-26 BE BE8900463A patent/BE1002024A6/xx active
- 1989-05-11 IT IT8920466A patent/IT1229272B/it active
- 1989-10-25 EP EP89119837A patent/EP0369216B1/de not_active Expired - Lifetime
- 1989-10-25 AT AT89119837T patent/ATE90563T1/de not_active IP Right Cessation
- 1989-10-25 ES ES89119837T patent/ES2057054T3/es not_active Expired - Lifetime
- 1989-10-25 DE DE8989119837T patent/DE58904722D1/de not_active Expired - Fee Related
- 1989-11-13 US US07/434,344 patent/US5002939A/en not_active Expired - Lifetime
- 1989-11-15 JP JP1297266A patent/JP2562210B2/ja not_active Expired - Fee Related
-
1993
- 1993-06-17 GR GR930400367T patent/GR3008170T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE58904722D1 (de) | 1993-07-22 |
| BE1002504A3 (fr) | 1991-03-05 |
| EP0369216B1 (de) | 1993-06-16 |
| DE3838716C2 (https=) | 1990-09-20 |
| ATE90563T1 (de) | 1993-07-15 |
| DE3838716A1 (de) | 1990-05-17 |
| US5002939A (en) | 1991-03-26 |
| IT8920466A0 (it) | 1989-05-11 |
| JPH02180830A (ja) | 1990-07-13 |
| EP0369216A2 (de) | 1990-05-23 |
| GR3008170T3 (https=) | 1993-09-30 |
| BE1002024A6 (fr) | 1990-05-22 |
| ES2057054T3 (es) | 1994-10-16 |
| IT1229272B (it) | 1991-07-26 |
| EP0369216A3 (en) | 1990-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4654370A (en) | Glyceryl valproates | |
| DE69327468T2 (de) | Verfahren zur reduktion der blutspiegel von gesamtcholesterin und ldl-cholesterin | |
| JP2562210B2 (ja) | ヘコゲニンのエステル誘導体含有医薬組成物 | |
| US3988446A (en) | Glycerides with anti-inflammatory properties | |
| JPS60158197A (ja) | 抗生物質およびその製法 | |
| DE3318989A1 (de) | Ss,(gamma)-dihydropolyprenylalkoholderivate und arzneimittel, welche diese enthalten | |
| JPS605580B2 (ja) | 新ナフタレン誘導体の製法 | |
| AU636328B2 (en) | 2,3,23-trihydroxy-urs-12-ene and its derivatives, processes for their preparation and their use | |
| CH644368A5 (en) | Hydroxylated pyrimidine derivatives, their preparation and therapeutic composition containing them | |
| JPS6011024B2 (ja) | 新規アミノ酸誘導体の製法 | |
| CA2056657A1 (en) | Pharmaceutical formulations containing a mixture of higher primary aliphatic alcohols in the treatment of hypercholesterolaemia and hyperlypoproteinaemia type ii and stimulation of sexual behaviour in animals and humans | |
| CA1173852A (en) | 2-amino-3-(halobenzoyl)-methylphenylacetic acids, esters and salts thereof | |
| US5149688A (en) | Methods, compounds, and compositions for immunosuppression | |
| US4975423A (en) | Inhibition of tumor development | |
| US3362879A (en) | Tyrosine tranquilizing compositions and methods of treatment | |
| JPS59108798A (ja) | 抗生物質ａ２０４ｉ誘導体の製造法 | |
| CN110384802A (zh) | 一种用于预防和/或治疗发热的药物、组合产品及其应用 | |
| US4542141A (en) | Compound having vasodilating, antiaggregating and hypocholesterolemic activities, process for the preparation thereof and pharmaceutical compositions therefrom | |
| JP2599163B2 (ja) | 家畜および家禽のサルモネラ・テイフィムリウム感染症の予防及び治療剤 | |
| US3843626A (en) | Anti-inflammatory compositions containing acylated-b-d-glucopyranosides and methods of using them | |
| US4883813A (en) | Method of treating inflammation in mammals utilizing ketobutyrolactones and furylbutyrolactones | |
| US3462534A (en) | Production of an antidepressant effect with esters of gallic acid | |
| GB2161074A (en) | Inhibition of tumour development | |
| US3053737A (en) | N-acetyl-p-aminophenol antiinflammatory steroid compositions | |
| US4092426A (en) | Novel aminobenzoic acid derivatives, process for preparing the same and pharmaceutical composition containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |